Weekly shot could replace daily insulin for thalassemia kids with diabetes

NCT ID NCT07370922

Completed Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a once-weekly injection called dulaglutide (a GLP-1 drug) against daily insulin in 80 children aged 10-18 with transfusion-dependent thalassemia and diabetes. The goal was to see if the weekly shot could control blood sugar just as well or better than insulin over 6 months. If successful, it could offer a simpler treatment option for these kids.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dulaglutide (a once-weekly injection)
What this could lead to: If it works, this could give children with thalassemia-related diabetes a simpler once-weekly injection instead of daily insulin shots.
What could go wrong: This is a small, early-phase trial with only 80 participants. The drug may not control blood sugar as well as insulin, and side effects like nausea or stomach issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSFUSION-DEPENDENT BETA-THALASSEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

beta-thalassemia major diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSFUSION-DEPENDENT BETA-THALASSEMIA

Contacts and locations

Locations

Faculty of medicine, Ain Shams University

Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.